Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
 Blood, 1 November 2004, Vol. 104, No. 9, pp. 2690-2696.
Prepublished online as a Blood First Edition Paper on July 13, 2004; DOI 10.1182/blood-2004-04-1616.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
2004-04-1616v1
104/9/2690    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pui, C.-H.
Right arrow Articles by Evans, W. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pui, C.-H.
Right arrow Articles by Evans, W. E.
Related Collections
Right arrow Neoplasia
Right arrow Oncogenes and Tumor Suppressors
Right arrow Clinical Trials and Observations
Right arrowRelated Article in Blood Online
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS

Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital

Ching-Hon Pui, John T. Sandlund, Deqing Pei, Dario Campana, Gaston K. Rivera, Raul C. Ribeiro, Jeffrey E. Rubnitz, Bassem I. Razzouk, Scott C. Howard, Melissa M. Hudson, Cheng Cheng, Larry E. Kun, Susana C. Raimondi, Frederick G. Behm, James R. Downing, Mary V. Relling, and William E. Evans

From the Departments of Hematology/Oncology, Pharmaceutical Sciences, Pathology, Biostatistics, and Radiology Sciences, St Jude Children's Research Hospital, Memphis, TN; and the College of Medicine and Pharmacy, University of Tennessee Health Sciences Center, Memphis, TN.

St Jude Total Therapy Study XIIIB for childhood acute lymphoblastic leukemia (ALL) incorporated more stringent risk classification, early intensification of intrathecal chemotherapy, reinduction treatment, and the addition of dexamethasone to postremission therapy to increase the proportion of event-free survivors without jeopardizing their quality of life. Cranial irradiation was reserved for the 12% of patients who had T-cell ALL and a presenting leukocyte count of 100 x 109/L or more, or CNS-3 (5 or more leukocytes/µL with identifiable blast cells in an atraumatic sample or the presence of cranial nerve palsy) status. Among the 247 consecutive patients enrolled in the study, 117 were classified as having lower-risk leukemia and received mainly antimetabolite-based continuation therapy; the 130 cases with higher-risk leukemia received more intensive continuation chemotherapy with multiple drug pairs administered in weekly rotation. The 5-year event-free survival estimate was 80.8% ± 2.6% (SE); the 8-year rate was 78.6% ± 5.8%. The 5-year cumulative risk of an isolated central nervous system (CNS) relapse was 1.7% ± 0.8%, and that of isolated plus combined CNS relapse was 3.0% ± 1.1%. The 5-year cumulative risks of etoposide-related myeloid malignancies were 1.8% ± 1.3% in the lower-risk patients who received a cumulative dose of 1.2 g/m2 and 5.0% ± 2.0% in the higher-risk patients who received a cumulative dose of up to 14.4 g/m2 (P = .18). Independent adverse prognostic features included the presence of MLL-AF4 or BCR-ABL fusion gene and minimal residual leukemia of 0.01% or more at the end of the 6-week remission induction phase. Our results suggest the efficacy of early intensification of intrathecal chemotherapy and provide the basis for studies omitting cranial irradiation altogether. (Blood. 2004;104:2690-2696)


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Related Article in Blood Online:

Great oaks from little acorns
Bruce Matthew Camitta
Blood 2004 104: 2617. [Full Text] [PDF]



This article has been cited by other articles:


Home page
 haematolHome page
R. K. Slany
The molecular biology of mixed lineage leukemia
Haematologica, July 1, 2009; 94(7): 984 - 993.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
C.-H. Pui, D. Campana, D. Pei, W. P. Bowman, J. T. Sandlund, S. C. Kaste, R. C. Ribeiro, J. E. Rubnitz, S. C. Raimondi, M. Onciu, et al.
Treating Childhood Acute Lymphoblastic Leukemia without Cranial Irradiation
N. Engl. J. Med., June 25, 2009; 360(26): 2730 - 2741.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
D. French, W. Yang, C. Cheng, S. C. Raimondi, C. G. Mullighan, J. R. Downing, W. E. Evans, C.-H. Pui, and M. V. Relling
Acquired variation outweighs inherited variation in whole genome analysis of methotrexate polyglutamate accumulation in leukemia
Blood, May 7, 2009; 113(19): 4512 - 4520.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
C. G. Mullighan, X. Su, J. Zhang, I. Radtke, L. A.A. Phillips, C. B. Miller, J. Ma, W. Liu, C. Cheng, B. A. Schulman, et al.
Deletion of IKZF1 and Prognosis in Acute Lymphoblastic Leukemia
N. Engl. J. Med., January 29, 2009; 360(5): 470 - 480.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
J. J. Yang, C. Cheng, W. Yang, D. Pei, X. Cao, Y. Fan, S. B. Pounds, G. Neale, L. R. Trevino, D. French, et al.
Genome-wide Interrogation of Germline Genetic Variation Associated With Treatment Response in Childhood Acute Lymphoblastic Leukemia
JAMA, January 28, 2009; 301(4): 393 - 403.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
T. S. Jones, S. C. Kaste, W. Liu, C. Cheng, W. Yang, K. G. Tantisira, C.-H. Pui, and M. V. Relling
CRHR1 Polymorphisms Predict Bone Density in Survivors of Acute Lymphoblastic Leukemia
J. Clin. Oncol., June 20, 2008; 26(18): 3031 - 3037.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. Oudot, M.-F. Auclerc, V. Levy, R. Porcher, C. Piguet, Y. Perel, V. Gandemer, M. Debre, C. Vermylen, B. Pautard, et al.
Prognostic Factors for Leukemic Induction Failure in Children With Acute Lymphoblastic Leukemia and Outcome After Salvage Therapy: The FRALLE 93 Study
J. Clin. Oncol., March 20, 2008; 26(9): 1496 - 1503.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. V. Barry, L. M. Vrooman, S. E. Dahlberg, D. S. Neuberg, B. L. Asselin, U. H. Athale, L. A. Clavell, E. C. Larsen, A. Moghrabi, Y. Samson, et al.
Absence of Secondary Malignant Neoplasms in Children With High-Risk Acute Lymphoblastic Leukemia Treated With Dexrazoxane
J. Clin. Oncol., March 1, 2008; 26(7): 1106 - 1111.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. Zhou, M. A Goldwasser, A. Li, S. E. Dahlberg, D. Neuberg, H. Wang, V. Dalton, K. D McBride, S. E. Sallan, L. B Silverman, et al.
Quantitative analysis of minimal residual disease predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL Consortium Protocol 95-01
Blood, September 1, 2007; 110(5): 1607 - 1611.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. R. Chauvenet, P. L. Martin, M. Devidas, S. B. Linda, B. A. Bell, J. Kurtzberg, J. Pullen, M. J. Pettenati, A. J. Carroll, J. J. Shuster, et al.
Antimetabolite therapy for lesser-risk B-lineage acute lymphoblastic leukemia of childhood: a report from Children's Oncology Group Study P9201
Blood, August 15, 2007; 110(4): 1105 - 1111.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
C. Flotho, E. Coustan-Smith, D. Pei, C. Cheng, G. Song, C.-H. Pui, J. R. Downing, and D. Campana
A set of genes that regulate cell proliferation predicts treatment outcome in childhood acute lymphoblastic leukemia
Blood, August 15, 2007; 110(4): 1271 - 1277.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. Kishi, C. Cheng, D. French, D. Pei, S. Das, E. H. Cook, N. Hijiya, C. Rizzari, G. L. Rosner, T. Frudakis, et al.
Ancestry and pharmacogenetics of antileukemic drug toxicity
Blood, May 15, 2007; 109(10): 4151 - 4157.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. J. Karimova, S. N. Rai, S. C. Howard, M. Neel, L. Britton, C.-H. Pui, and S. C. Kaste
Femoral Head Osteonecrosis in Pediatric and Young Adult Patients With Leukemia or Lymphoma
J. Clin. Oncol., April 20, 2007; 25(12): 1525 - 1531.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
N. Hijiya, M. M. Hudson, S. Lensing, M. Zacher, M. Onciu, F. G. Behm, B. I. Razzouk, R. C. Ribeiro, J. E. Rubnitz, J. T. Sandlund, et al.
Cumulative Incidence of Secondary Neoplasms as a First Event After Childhood Acute Lymphoblastic Leukemia
JAMA, March 21, 2007; 297(11): 1207 - 1215.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. Barry, D. J. DeAngelo, D. Neuberg, K. Stevenson, M. L. Loh, B. L. Asselin, R. D. Barr, L. A. Clavell, C. A. Hurwitz, A. Moghrabi, et al.
Favorable Outcome for Adolescents With Acute Lymphoblastic Leukemia Treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols
J. Clin. Oncol., March 1, 2007; 25(7): 813 - 819.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Moghrabi, D. E. Levy, B. Asselin, R. Barr, L. Clavell, C. Hurwitz, Y. Samson, M. Schorin, V. K. Dalton, S. E. Lipshultz, et al.
Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia
Blood, February 1, 2007; 109(3): 896 - 904.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
N. Hijiya, J. C. Panetta, Y. Zhou, E. P. Kyzer, S. C. Howard, S. Jeha, B. I. Razzouk, R. C. Ribeiro, J. E. Rubnitz, M. M. Hudson, et al.
Body mass index does not influence pharmacokinetics or outcome of treatment in children with acute lymphoblastic leukemia
Blood, December 15, 2006; 108(13): 3997 - 4002.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. Jeha, F. Behm, D. Pei, J. T. Sandlund, R. C. Ribeiro, B. I. Razzouk, J. E. Rubnitz, N. Hijiya, S. C. Howard, C. Cheng, et al.
Prognostic significance of CD20 expression in childhood B-cell precursor acute lymphoblastic leukemia
Blood, November 15, 2006; 108(10): 3302 - 3304.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Holleman, M. L. den Boer, M. H. Cheok, K. M. Kazemier, D. Pei, J. R. Downing, G. E. Janka-Schaub, U. Gobel, U. B. Graubner, C.-H. Pui, et al.
Expression of the outcome predictor in acute leukemia 1 (OPAL1) gene is not an independent prognostic factor in patients treated according to COALL or St Jude protocols
Blood, September 15, 2006; 108(6): 1984 - 1990.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
Y. Matloub, S. Lindemulder, P. S. Gaynon, H. Sather, M. La, E. Broxson, R. Yanofsky, R. Hutchinson, N. A. Heerema, J. Nachman, et al.
Intrathecal triple therapy decreases central nervous system relapse but fails to improve event-free survival when compared with intrathecal methotrexate: results of the Children's Cancer Group (CCG) 1952 study for standard-risk acute lymphoblastic leukemia, reported by the Children's Oncology Group
Blood, August 15, 2006; 108(4): 1165 - 1173.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
C. Flotho, E. Coustan-Smith, D. Pei, S. Iwamoto, G. Song, C. Cheng, C.-H. Pui, J. R. Downing, and D. Campana
Genes contributing to minimal residual disease in childhood acute lymphoblastic leukemia: prognostic significance of CASP8AP2
Blood, August 1, 2006; 108(3): 1050 - 1057.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
E. Coustan-Smith, R. C. Ribeiro, P. Stow, Y. Zhou, C.-H. Pui, G. K. Rivera, F. Pedrosa, and D. Campana
A simplified flow cytometric assay identifies children with acute lymphoblastic leukemia who have a superior clinical outcome
Blood, July 1, 2006; 108(1): 97 - 102.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. Nagayama, D. Tomizawa, K. Koh, Y. Nagatoshi, N. Hotta, T. Kishimoto, Y. Takahashi, T. Kuno, K. Sugita, T. Sato, et al.
Infants with acute lymphoblastic leukemia and a germline MLL gene are highly curable with use of chemotherapy alone: results from the Japan Infant Leukemia Study Group
Blood, June 15, 2006; 107(12): 4663 - 4665.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. Eapen, E. Raetz, M.-J. Zhang, C. Muehlenbein, M. Devidas, T. Abshire, A. Billett, A. Homans, B. Camitta, W. L. Carroll, et al.
Outcomes after HLA-matched sibling transplantation or chemotherapy in children with B-precursor acute lymphoblastic leukemia in a second remission: a collaborative study of the Children's Oncology Group and the Center for International Blood and Marrow Transplant Research
Blood, June 15, 2006; 107(12): 4961 - 4967.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. M. W.M. te Loo, W. A. Kamps, A. van der Does-van den Berg, E. R. van Wering, and S. S.N. de Graaf
Prognostic Significance of Blasts in the Cerebrospinal Fluid Without Pleiocytosis or a Traumatic Lumbar Puncture in Children With Acute Lymphoblastic Leukemia: Experience of the Dutch Childhood Oncology Group
J. Clin. Oncol., May 20, 2006; 24(15): 2332 - 2336.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Roentgenol.Home page
E. J. Karimova, S. N. Rai, X. Deng, D. J. Ingle, A. C. Ralph, M. D. Neel, and S. C. Kaste
MRI of Knee Osteonecrosis in Children with Leukemia and Lymphoma: Part 1, Observer Agreement
Am. J. Roentgenol., February 1, 2006; 186(2): 470 - 476.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Holleman, M. L. den Boer, R. X. de Menezes, M. H. Cheok, C. Cheng, K. M. Kazemier, G. E. Janka-Schaub, U. Gobel, U. B. Graubner, W. E. Evans, et al.
The expression of 70 apoptosis genes in relation to lineage, genetic subtype, cellular drug resistance, and outcome in childhood acute lymphoblastic leukemia
Blood, January 15, 2006; 107(2): 769 - 776.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
C.-H. Pui and W. E. Evans
Treatment of Acute Lymphoblastic Leukemia
N. Engl. J. Med., January 12, 2006; 354(2): 166 - 178.
[Full Text] [PDF]

Home page
 ASH Education BookHome page
C.-H. Pui
Central Nervous System Disease in Acute Lymphoblastic Leukemia: Prophylaxis and Treatment
Hematology, January 1, 2006; 2006(1): 142 - 146.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C.-H. Pui, D. Pei, J. T. Sandlund, D. Campana, R. C. Ribeiro, B. I. Razzouk, J. E. Rubnitz, S. C. Howard, N. Hijiya, S. Jeha, et al.
Risk of Adverse Events After Completion of Therapy for Childhood Acute Lymphoblastic Leukemia
J. Clin. Oncol., November 1, 2005; 23(31): 7936 - 7941.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
H. G. Einsiedel, A. von Stackelberg, R. Hartmann, R. Fengler, M. Schrappe, G. Janka-Schaub, G. Mann, K. Hahlen, U. Gobel, T. Klingebiel, et al.
Long-Term Outcome in Children With Relapsed ALL by Risk-Stratified Salvage Therapy: Results of Trial Acute Lymphoblastic Leukemia-Relapse Study of the Berlin-Frankfurt-Munster Group 87
J. Clin. Oncol., November 1, 2005; 23(31): 7942 - 7950.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Pession, M. G. Valsecchi, G. Masera, W. A. Kamps, E. Magyarosy, C. Rizzari, E. R. van Wering, L. Lo Nigro, A. van der Does, F. Locatelli, et al.
Long-Term Results of a Randomized Trial on Extended Use of High Dose L-Asparaginase for Standard Risk Childhood Acute Lymphoblastic Leukemia
J. Clin. Oncol., October 1, 2005; 23(28): 7161 - 7167.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
G. Zaza, M. Cheok, W. Yang, J. C. Panetta, C.-H. Pui, M. V. Relling, and W. E. Evans
Gene expression and thioguanine nucleotide disposition in acute lymphoblastic leukemia after in vivo mercaptopurine treatment
Blood, September 1, 2005; 106(5): 1778 - 1785.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. C. C. Rocha, C. Cheng, W. Liu, S. Kishi, S. Das, E. H. Cook, J. T. Sandlund, J. Rubnitz, R. Ribeiro, D. Campana, et al.
Pharmacogenetics of outcome in children with acute lymphoblastic leukemia
Blood, June 15, 2005; 105(12): 4752 - 4758.
[Abstract] [Full Text] [PDF]


click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2004 by American Society of Hematology         Online ISSN: 1528-0020